Trial finds new drug safe, effective to treat deadliest form of epilepsy
MSN highlights UC trial data presentation
MSN highlighted research presented by the University of Cincinnati’s Brandon Foreman that found ganaxolone is a safe and effective treatment for refractory status epilepticus, the most severe and deadly form of epilepsy where seizures do not stop.
Current standards of care include administering an intravenous antiseizure medicine, a benzodiazepine such as midazolam, as soon as possible to stop seizures. When those do not work, a second intravenous antiseizure medication is started, but about one quarter of patients continue to experience seizures, termed refractory status epilepticus (RSE).
The Phase 3 RAndomized Therapy In Status Epilepticus (RAISE) trial tested a neurosteroid called ganaxolone for patients hospitalized with seizures that progressed to RSE despite receiving two or more antiseizure medications.
Researchers found a statistically significant proportion of patients who received ganaxolone stopped seizing within 30 minutes: 80% of those patients receiving ganaxolone saw their RSE stop a median of just 4 minutes after the drug was administered.
“Ganaxolone as a rapidly effective medication would fill a specific gap in care for which there are no current treatment options beyond intubation and anesthetic medications if standard antiseizure medications fail,” he said. “It is recognized that the use of anesthetics increases the morbidity and mortality of RSE, so ganaxolone has the potential to save lives and avoid prolonged intensive care.”
Featured photo at top of Foreman looking at a brain monitor. Photo/Andrew Higley/UC Marketing + Brand.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.